Lutetium-177 treatment for advanced somatostatin-positive tumors
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study looks at outcomes for adults with tumors that are advanced (can’t be fully removed or has spread) and are getting worse, where tests show somatostatin receptors. It aims to understand how treatment with lutetium-177 helps people in this situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can give written consent before any study information is collected
- You are 18 years or older
- Your tumor is advanced: either unresectable or metastatic
- Your cancer is progressive, meaning it is getting worse
- Your tumor test shows it is somatostatin receptor positive
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized way to give a radioactive drug called Lutathera to people with neuroendocrine tumors (NETs). The goal is to see if adjusting the dose based on how your body absorbs it can be more effective.
This trial tests a type of radiation therapy called Lu-177 Dotatoc (PRRT) for people with neuroendocrine tumors or other cancers that have high levels of a specific protein (sst2). It may be an option when standard treatments stop working or aren't available.
This trial tests a radioactive drug called Lutetium-177 Oxodotreotide (a type of PRRT) for people with advanced neuroendocrine tumors that have already been treated with other therapies and are still growing. The drug targets somatostatin receptors on tumor cells to deliver radiation directly to the cancer.
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
This Phase 3 trial tests lutetium (Lu-177) oxodotreotide, a targeted treatment, for people with advanced gut and pancreas neuroendocrine tumors that are low or medium grade (G1 or G2). The study will see whether it helps control the cancer and symptoms in the right patients.
This trial tests a radioactive drug called Lu-177 edotreotide for children with a certain type of tumor (SSTR-positive) that hasn't responded to other treatments. The goal is to find the right dose and see how safe it is.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.